Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More

(MoneyWatch)  Glaxo reorganizes U.S. operations -- Final details of the changes are planned for release on Wednesday, November 5. Cuts to sales rep teams are expected; a new head of Glaxo North America (the current head, Chris Viehbacher, is leaving to lead Sanofi), however, will not yet be named. [Source: Pharmalot]

Connecticut congressmen ask Pfizer to keep U.S. jobs -- Pfizer has significant operations in the state, and fears have grown that the company is grooming foreign workers to take over the IT work Connecticut contractors currently perform. Senator Chris Dodd and Representative Joe Courtney voiced their concerns in an open letter. [Source: WSJ Health Blog]

AstraZeneca executive Patterson to retire -- In March, John Patterson will leave his post leading the company's development organization. [Source: PharmaGossip]

DTC advertising not earning its keep -- ... or so says John Mack, at the Pharma Marketing Blog. Mack crunched some numbers and determined that, contrary to conventional wisdom, pharma would profit from the elimination of direct-to-consumer TV ads (i.e., sales generated by DTC ads don't cover their cost). Agree or disagree with his math, it's a provocative point. [Source: Pharma Marketing Blog]